Could cause temporary or reversible harm; serious harm is unlikely.
cGMP deviations
| Brand name | AMLODIPINE AND OLMESARTAN MEDOXOMIL |
| Generic name | AMLODIPINE AND OLMESARTAN MEDOXOMIL |
| Active ingredient(s) | AMLODIPINE BESYLATE, OLMESARTAN MEDOXOMIL |
| Distributed by / for | Macleods Pharma USA, Inc., Plainsboro, NJ 08536 |
| NDC | 33342-192-07 |
| Full product label | Amlodipine and Olmesartan Medoxomil Tablets, 10 mg /20 mg, 30-count bottles, Rx only, Manufactured for: Macleods Pharma USA, Inc., Plainsboro, NJ 08536, Manufactured by: Macleods Pharmaceuticals, Ltd, Baddi, Himachal Pradesh, INDIA, NDC 33342-192-07. |
| Recalling firm | Macleods Pharma Usa Inc |
| Distribution | USA Nationwide |
| Quantity | 3,672 bottles |
| Recall initiated | 2022-02-15 |
| Report date | 2022-03-09 |
| Recall completed | 2023-02-17 |
| Recall number | D-0632-2022 |
| Classification | Class II |
| FDA status | Terminated |
| Origin on file | Plainsboro NJ United States |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗